Overview: Parathyroid Hormone Antibody TestIntroduction: The Parathyroid Hormone Antibody Test detects PTH antibodies to diagnose parathyroid disorders, causing bone pain. Following 2023 Endocrine Society guidelines, it uses immunoassays for high specificity, supporting hormonal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune parathyroid disease.
Other Names: PTH Antibody Assay, Parathyroid Autoimmune Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: PTH antibody testing began in the 1990s with autoimmune endocrine research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects PTH antibodies to diagnose parathyroid disorders, guides treatment, and evaluates patients with bone pain.
Test Parameters: 1. PTH Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of bone pain or parathyroid symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bone pain, hypocalcemia, or history of autoimmune disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, parathyroid disorder implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect PTH antibodies. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for autoimmune parathyroid diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive PTH antibodies confirm autoimmune parathyroid disease, guiding immunosuppressive therapy. Negative results may require intact PTH testing.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Intact PTH, calcium levels, or autoimmune panel to confirm parathyroid disorder diagnosis.
Test Limitations: Non-specific for certain autoimmune conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: Endocrine Society Parathyroid Guidelines, 2023; Journal of Clinical Endocrinology, Bilezikian JP, 2022.
